Zeta CD14 Antibody. Zeta’s recombinant mouse antibody recognizes CD14, a receptor expressed strongly on monocytes and macrophages and weakly on the surface of neutrophils and detects antigenic molecules on the surface of various microorganisms. CD14 (also known as lipopolysaccharide receptor) is a protein of 55kDa. CD14 is anchored to cells by linkage to glycosylphosphatidylinositol (GPI) and functions as a high-affinity receptor for complexes of LPS and LPS binding protein (LBP). Soluble CD14 binds to LPS and acts at a physiological concentration as an LPS agonist while at higher concentrations, acts as an LPS antagonizing effect in cell activation.
CD14 is an important pattern recognition receptor that detects antigenic molecules on the surface of various microorganisms. CD14 mutations can prevent adequate inflammatory response to infection, leading to systemic infections. Macrophages with a protein complex of CD14, MD2 and TLR4 bind to LPS, causing macrophage activation and release of cytokines where overstimulation may cause toxic shock syndrome.
The CD14 antibody is used to identify mature monocytes and macrophages where normal staining includes macrophages, monocytes, Langerhans cells, dendritic cells, B cells and granulocytes. CD14 is also expressed in chronic myelomonocytic leukemia and histiocytic scarcoma.
Zeta Corporation is a leader in recombinant monoclonal IVD antibodies for immunohistochemistry (IHC) offering 400+ tumor and tissue specific relevant products developed by a pathologist for pathologists. Visit Precision Recombinant Antibodies – IVD Antibodies – About Zeta Corporation (zeta-corp.com) to learn more about Zeta Corporation.